Cargando…

The Chinese herbal formula Huoxiang Zhengqi for diarrhea-predominant irritable bowel syndrome (CHAIRS): a study protocol for a double-blinded randomized controlled trial

BACKGROUND: Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common chronic digestive disease. Recent observational studies have reported that the Chinese herbal formula Huoxiang Zhengqi (HXZQ) can relieve IBS-D symptoms, but no high-level evidence is presented. Therefore, we want to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Xiaohui, Xuan, Meiling, Zheng, Huan, Qin, Shumin, Wu, Haomeng, Huang, Shaogang, Wen, Zehuai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314472/ https://www.ncbi.nlm.nih.gov/pubmed/34311755 http://dx.doi.org/10.1186/s13063-021-05444-w

Ejemplares similares

Chinese Herbal Formula Huoxiang Zhengqi for Dampness Pattern in Atopic Dermatitis and Diarrhea-Predominant Irritable Bowel Syndrome: Rationale and Design of a Master Protocol
por: Huang, Qian, et al.
Publicado: (2021)

The Chinese herbal formula Huoxiang Zhengqi for atopic dermatitis with dampness pattern (CHARM): a study protocol for a double-blinded randomized controlled trial
por: Xuan, Meiling, et al.
Publicado: (2021)

The Chinese Herbal Formula Huoxiang Zhengqi Dropping Pills Prevents Acute Intestinal Injury Induced by Heatstroke by Increasing the Expression of Claudin-3 in Rats
por: Li, Yu-Nong, et al.
Publicado: (2022)

Protective Effect of Huoxiang Zhengqi Oral Liquid on Intestinal Mucosal Mechanical Barrier of Rats with Postinfectious Irritable Bowel Syndrome Induced by Acetic Acid
por: Liu, Yao, et al.
Publicado: (2014)

Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome
por: Zhan, Kai, et al.
Publicado: (2020)

Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial
por: Xiao, Mingzhong, et al.
Publicado: (2020)

Effect of Huoxiang Zhengqi Pill on Early Neurological Deterioration in Patients with Acute Ischemic Stroke Undergoing Recanalization Therapy and Predictive Effect of Essen Score
por: Huang, Zhi-Xin, et al.
Publicado: (2020)

Modulatory Effects of Huoxiang Zhengqi Oral Liquid on Gut Microbiome Homeostasis Based on Healthy Adults and Antibiotic-Induced Gut Microbial Dysbiosis Mice Model
por: Gao, Min, et al.
Publicado: (2022)

Targeted therapies for diarrhea-predominant irritable bowel syndrome
por: Olden, Kevin W
Publicado: (2012)

Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
por: Lacy, Brian E
Publicado: (2016)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Özdener, Ayşe Elif, et al.
Publicado: (2017)

Huoxiang Zhengqi alleviates azoxymethane/dextran sulfate sodium-induced colitis-associated cancer by regulating Nrf2/NF-κB/NLRP3 signaling
por: Dong, Mingyuan, et al.
Publicado: (2022)

Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized, multiple-blind, placebo-controlled trial
por: Liang, Shi-Bing, et al.
Publicado: (2022)

Systematic review and meta-analysis of Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: Evidence for clinical practice and future trials
por: Liang, Shi-Bing, et al.
Publicado: (2022)

Misinterpreting Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea: Pathophysiological Highlights
por: Sciumè, Giusi Desirè, et al.
Publicado: (2023)

Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update
por: Andrews, Christopher N, et al.
Publicado: (2019)

Clinical evidence of acupuncture and moxibustion for irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials
por: Yang, Yuanming, et al.
Publicado: (2022)

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016)

Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2018)

Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome
por: Li, Pingping, et al.
Publicado: (2020)

Comparison of Quality of Life and Psychiatric Symptoms Between Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Those With Constipation-Predominant Irritable Bowel Syndrome
por: BOUSABA, J., et al.
Publicado: (2023)

Exploring the synergistic pharmacological mechanism of Huoxiang Drink against irritable bowel syndrome by integrated data mining and network pharmacology
por: Wang, Ruo-Hui, et al.
Publicado: (2023)

Huoxiang Zhengqi Oral Liquid Attenuates LPS-Induced Acute Lung Injury by Modulating Short-Chain Fatty Acid Levels and TLR4/NF-κB p65 Pathway
por: Tang, Ruying, et al.
Publicado: (2023)

Dysregulation of GABAergic Signalling Contributes in the Pathogenesis of Diarrhea-predominant Irritable Bowel Syndrome
por: Aggarwal, Surbhi, et al.
Publicado: (2018)

Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome
por: Arrouk, Rami, et al.
Publicado: (2018)

Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome
por: Katsumata, Ryo, et al.
Publicado: (2017)

Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome
por: Mei, Lijun, et al.
Publicado: (2021)

Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome
por: Martoni, Christopher J, et al.
Publicado: (2023)

Metabolomics analysis of herb-partitioned moxibustion treatment on rats with diarrhea-predominant irritable bowel syndrome
por: Lin, Xianwei, et al.
Publicado: (2019)

Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: A randomized controlled trial
por: Zheng, Hui, et al.
Publicado: (2016)

Efficacy and Safety of Acupoint Catgut Embedding for Diarrhea-Predominant Irritable Bowel Syndrome and Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
por: Wu, Jing, et al.
Publicado: (2020)

Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
por: Mangel, Allen W, et al.
Publicado: (2012)

Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome
por: Carroll, Ian M, et al.
Publicado: (2010)

Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome
por: GAO, JINGGUO
Publicado: (2013)

Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome
por: Chiba, Toshimi, et al.
Publicado: (2013)

Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects
por: Pimentel, Mark, et al.
Publicado: (2015)

Inhibitory effects of patchouli alcohol on stress-induced diarrhea-predominant irritable bowel syndrome
por: Zhou, Tian-Ran, et al.
Publicado: (2018)

Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome
por: Liu, De-Rong, et al.
Publicado: (2018)

Capsule Endoscopy in Refractory Diarrhea-Predominant Irritable Bowel Syndrome and Functional Abdominal Pain
por: Valero, Manuel, et al.
Publicado: (2018)

Claudin-2 expression is upregulated in the ileum of diarrhea predominant irritable bowel syndrome patients
por: Ishimoto, Haruka, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2m3fhepvnk687cpskh2sf25lco